Back to search
FDAFDA · Food and drugs·Recall number Z-2206-2020

Medtronic Implantable Insulin Pump System, REF: MMT-2007D, Sterile EO, CE 0459 UDI: 00763000043001

Published June 10, 2020 · Recall initiated: April 10, 2020

Summary

FDA records medical device Class II recall Z-2206-2020, published June 10, 2020 and initiated April 10, 2020. Recalling firm: Medtronic Inc.; Status: Terminated; Reported quantity: 24 Pumps; Lot: Device not distributed within the US. All Pump lots produced May 21, 2019 to present containing the following serial numbers: 31359, 31360, and 31332. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Internal testing results showed endotoxin-related test result did not meet specifications for implantable insulin pump. If pumps have higher than allowed endotoxin levels, patients may have an effect of fever, hypotension, anaphylactic shock, hyperglycemia, or diabetic ketoacidosis (DKA), potentially followed by secondary multi-organ failure (primarily renal and hepatic) and/or death.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Medtronic Inc.
Distributor
No US Distribution. OUS: Netherlands, France, and Sweden
Lot
Device not distributed within the US. All Pump lots produced May 21, 2019 to present containing the following serial numbers: 31359, 31360, and 31332
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Medtronic Implantable Insulin Pump System, REF: MMT-2007D, Sterile EO, CE 0459 UDI: 00763000043001 recalled?

Yes. FDA published recall Z-2206-2020 on June 10, 2020. Reported hazard: Internal testing results showed endotoxin-related test result did not meet specifications for implantable insulin pump. If pumps have higher than allowed endotoxin levels, patients may have an effect of fever, hypotension, anaphylactic shock, hyperglycemia, or diabetic ketoacidosis (DKA), potentially followed by secondary multi-organ failure (primarily renal and hepatic) and/or death.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone